TY  - GEN

T1  - P73 Laboratory safety from a 16-week phase III study of dupilumab in patients aged 6 months–5 years with moderate-to-severe atopic dermatitis

PY  - 2023/06/26

AU  - Paller AS

AU  - Cork MJ

AU  - Wollenberg A

AU  - Siegfried EC

AU  - Gonzalez ME

AU  - Lockshin B

AU  - Khokhar FA

AU  - Chen Z

AU  - Gonzalez T

AU  - Simcox E

AU  - Prescilla R

ED  - 

Y2  - 2024/12/22

ER  -